Copyright © 2000 by the European Society of Cardiology.
Editorial
Is more better? About dose levels of ACE inhibitors in chronic heart failure
Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden
References
- Flather M, Yusuf S, Kober L. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:15751581[CrossRef][ISI][Medline]
- Lancet. 1999;353:913[CrossRef][ISI][Medline]
- Lancet. 1999;353:20012007[CrossRef][ISI][Medline]
- Packer M. Pathophysiology of chronic heart failure. Division of Circulatory Physiology, Columbia University, College of Physicians and Surgeons, New York, NY 10032. Lancet. 1992;340:8892[CrossRef][ISI][Medline]
- Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709717
[Abstract/Free Full Text] - Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor. JAMA. 1995;273:14501456
[Abstract/Free Full Text] - Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145153
[Abstract/Free Full Text] - Pacher R, Globits S, Bergler Klein J. Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J. 1993;14:273278
[Abstract/Free Full Text] - MacFayden RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82:5761
[Abstract/Free Full Text] - Packer M, Poole-Wilson PA, Armstrong PW. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:23122318
[Abstract/Free Full Text] - Rydén L, Armstrong PW, Cleland JG. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000;21:19671978
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||